Quest Diagnostics Investments, Inc.

Kerry Group Services International Limited

Peter Lee

Michelle M Tabb

Albert Castro

Jules Chen

Lakshmi Nair

Raymond Huang

Kristin Ramos

Maria Vestal

Li Pan

Lucien Jacky

Jose Matud

Rajesh Potineni

Yingshuang Lu

John Kailemia Muchena

Celia Chee

The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.

Methods for detecting norovirus

Methods for detecting Norovirus

Methods of preparing a hemicellulose-product and a holocellulose-product from a carbohydrate-rich material, including spend coffee grounds, are described. Hemicellulose-products and holocellulose-products produced according to these methods are also described.

Composition and methods for preparing hemicellulose-rich extract from spend coffee ground

Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.

Molecular detection of enterovirus and parechovirus

Disclosed are methods for identifying the presence or absence of a target nucleic acid from one or more organisms in a biological sample, said method comprising: (a) spinning the sample at a rotational velocity sufficient to pellet cellular debris and fluorescence inhibitors present within the sample and reduce fluorescence interference or quenching in the sample; and (b) directly amplifying and detecting the target nucleic acid in the sample.

Amplification and detection of nucleic acids in a biological sample

Growing community of inventors

Tustin, CA, United States of America

Peter Lee